Man Group PLC Intercept Pharmaceuticals, Inc. Transaction History

Man Group PLC

$37.6 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$12.53 - $21.71 $356,917 - $618,409	28,485 New	28,485 $382,000
Q2 2022 Aug 15, 2022	SELL	$11.23 - $19.59 $50,535 - $88,155	-4,500 Reduced 18.86%	19,355 $267,000
Q1 2022 May 16, 2022	BUY	$13.37 - $17.79 $318,941 - $424,380	23,855 New	23,855 $388,000
Q1 2021 May 17, 2021	SELL	$19.33 - $37.75 $1.19 Million - $2.33 Million	-61,718 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$24.48 - $42.47 $1.42 Million - $2.46 Million	-57,979 Reduced 48.44%	61,718 $1.52 Million
Q3 2020 Nov 16, 2020	SELL	$39.09 - $53.44 $408,138 - $557,967	-10,441 Reduced 8.02%	119,697 $4.96 Million
Q2 2020 Aug 14, 2020	BUY	$46.7 - $92.04 $6.08 Million - $12 Million	130,138 New	130,138 $6.24 Million
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $617,622 - $1.52 Million	-12,774 Closed	0 $0
Q4 2019 Feb 18, 2020	SELL	$57.36 - $124.1 $1.31 Million - $2.84 Million	-22,914 Reduced 64.21%	12,774 $1.58 Million
Q3 2019 Nov 14, 2019	BUY	$58.69 - $80.46 $1.67 Million - $2.29 Million	28,496 Added 396.22%	35,688 $2.37 Million
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $679,320 - $1.05 Million	-8,735 Reduced 54.84%	7,192 $572,000
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $1.03 Million - $1.35 Million	11,165 Added 234.46%	15,927 $1.78 Million
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $36,374 - $53,619	424 Added 9.77%	4,762 $480,000
Q3 2018 Nov 14, 2018	SELL	$88.49 - $127.55 $60,704 - $87,499	-686 Reduced 13.65%	4,338 $548,000
Q2 2018 Aug 14, 2018	SELL	$60.0 - $85.67 $16,560 - $23,644	-276 Reduced 5.21%	5,024 $422,000
Q1 2018 May 15, 2018	BUY	$52.72 - $67.25 $279,416 - $356,425	5,300 New	5,300 $326,000

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account